Neuropeptidomics of mouse hypothalamus after imipramine treatment reveal somatostatin as a potential mediator of antidepressant effects

Excessive activation of the hypothalamic-pituitary-adrenal (HPA) axis has been associated with numerous diseases, including depression, and the tricyclic antidepressant imipramine has been shown to suppress activity of the HPA axis. Central hypothalamic control of the HPA axis is complex and involves a number of neuropeptides released from multiple hypothalamic subnuclei. The present study was therefore designed to determine the effects of imipramine administration on the mouse hypothalamus using a peptidomics approach. Among the factors found to be downregulated after acute (one day) or chronic (21 days) imipramine administration were peptides derived from secretogranin 1 (chromogranin B) as well as peptides derived from cerebellin precursors. In contrast, peptides SRIF-14 and SRIF-28 (1-11) derived from somatostatin (SRIF, somatotropin release inhibiting factor) were significantly upregulated by imipramine in the hypothalamus. Because diminished SRIF levels have long been known to occur in depression, a second part of the study investigated the roles of individual SRIF receptors in mediating potential antidepressant effects. SRA880, an antagonist of the somatostatin-1 autoreceptor (sst1) which positively modulates release of endogenous SRIF, was found to synergize with imipramine in causing antidepressant-like effects in the tail suspension test. Furthermore, chronic co-administration of SRA880 and imipramine synergistically increased BDNF mRNA expression in the cerebral cortex. Application of SRIF or L054264, an sst2 receptor agonist, but not L803807, an sst4 receptor agonist, increased phosphorylation of CaMKII and GluR1 in cerebrocortical slices. Our present experiments thus provide evidence for antidepressant-induced upregulation of SRIF in the brain, and strengthen the notion that augmented SRIF expression and signaling may counter depressive-like symptoms. This article is part of a Special Issue entitled 'Anxiety and Depression'.

[1]  L. Vécsei,et al.  Effects of somatostatin-28 and some of its fragments and analogs on open-field behavior, barrel rotation, and shuttle box learning in rats , 1990, Psychoneuroendocrinology.

[2]  Antidepressants Influence Somatostatin Levels and Receptor Pharmacology in Brain , 2009, Neuropsychopharmacology.

[3]  P. Svenningsson,et al.  Peptidomics-based discovery of novel neuropeptides. , 2003, Journal of proteome research.

[4]  Y. Wong,et al.  Activation of nuclear factor {kappa}B by somatostatin type 2 receptor in pancreatic acinar AR42J cells involves G{alpha}14 and multiple signaling components: a mechanism requiring protein kinase C, calmodulin-dependent kinase II, ERK, and c-Src. , 2005, The Journal of biological chemistry.

[5]  T. Troxler,et al.  SRA880, in vitro characterization of the first non-peptide somatostatin sst(1) receptor antagonist. , 2004, Neuroscience letters.

[6]  Christian Bruns,et al.  Opportunities in somatostatin research: biological, chemical and therapeutic aspects , 2003, Nature Reviews Drug Discovery.

[7]  G. Fink,et al.  Somatostatin-28 is an hormonally active peptide secreted into hypophysial portal vessel blood , 1983, Brain Research.

[8]  G. Fink,et al.  Somatostatin-28(1-12)-like immunoreactive substance is secreted into hypophysial portal vessel blood in the rat. , 1984, Neuroendocrinology.

[9]  P. Svenningsson,et al.  Biphasic changes in locomotor behavior and in expression of mRNA for NGFI-A and NGFI-B in rat striatum following acute caffeine administration , 1995, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[10]  D. Hoyer,et al.  The somatostatin sst1 receptor: an autoreceptor for somatostatin in brain and retina? , 2006, Pharmacology & therapeutics.

[11]  U. Lepola,et al.  Long-term effects of alprazolam and imipramine on cerebrospinal fluid monoamine metabolites and neuropeptides in panic disorder. , 1989, Neuropsychobiology.

[12]  N. Yamada,et al.  Chronic administration of tricyclic antidepressants suppresses hypothalamo-pituitary-adrenocortical activity in male rats , 1988, Psychoneuroendocrinology.

[13]  J. Morgan,et al.  Isolation and sequencing of two cerebellum-specific peptides. , 1984, Proceedings of the National Academy of Sciences of the United States of America.

[14]  A. Grossman,et al.  THE PITUITARY‐ADRENAL RESPONSE TO CRF‐41 IS UNALTERED BY INTRAVENOUS SOMATOSTATIN IN NORMAL SUBJECTS , 1989, Clinical endocrinology.

[15]  P. Greengard,et al.  Diverse Psychotomimetics Act Through a Common Signaling Pathway , 2003, Science.

[16]  Leonid Zamdborg,et al.  Endogenous Peptide Discovery of the Rat Circadian Clock a Focused Study of the Suprachiasmatic Nucleus by Ultrahigh Performance Tandem Mass Spectrometry* □ S , 2022 .

[17]  Q. Pittman,et al.  Somatostatin(14) and -(28) but not somatostatin(1–12) hyperpolarize CA1 pyramidal neurons in vitro , 1988, Brain Research.

[18]  G. Chrousos.  Stress and disorders of the stress system , 2009, Nature Reviews Endocrinology.

[19]  D. O'Connor,et al.  The chromogranin-secretogranin family. , 2003, The New England journal of medicine.

[20]  P. Greengard,et al.  Regulation of Phosphorylation of the GluR1 AMPA Receptor in the Neostriatum by Dopamine and Psychostimulants In Vivo , 2000, The Journal of Neuroscience.

[21]  George Paxinos,et al.  The Mouse Brain in Stereotaxic Coordinates , 2001 .

[22]  J. Cryan,et al.  The tail suspension test as a model for assessing antidepressant activity: Review of pharmacological and genetic studies in mice , 2005, Neuroscience & Biobehavioral Reviews.

[23]  J. Herman,et al.  Neural regulation of endocrine and autonomic stress responses , 2009, Nature Reviews Neuroscience.

[24]  C. Dickson,et al.  Anxiolytic and antidepressant effects of intracerebroventricularly administered somatostatin: Behavioral and neurophysiological evidence , 2008, Neuroscience.

[25]  Fa-Yun Che,et al.  Optimization of neuropeptide extraction from the mouse hypothalamus. , 2007, Journal of proteome research.

[26]  D. Hoyer,et al.  The somatostatin receptor (sst1) modulates the release of somatostatin in the nucleus accumbens of the rat , 2004, Neuropharmacology.

[27]  D. Hoyer,et al.  SRA880, in vitro characterization of the first non-peptide somatostatin sst1 receptor antagonist , 2004, Neuroscience Letters.

[28]  I. Lucki,et al.  Limitations on the use of the C57BL/6 mouse in the tail suspension test , 2001, Psychopharmacology.

[29]  M. Herkenham,et al.  St John's wort, hypericin, and imipramine: a comparative analysis of mRNA levels in brain areas involved in HPA axis control following short-term and long-term administration in normal and stressed rats , 2001, Molecular Psychiatry.

[30]  David Fenyö,et al.  An automated method for scanning LC-MS data sets for significant peptides and proteins, including quantitative profiling and interactive confirmation. , 2007, Journal of proteome research.

[31]  H. Gershenfeld,et al.  An exploratory factor analysis of the Tail Suspension Test in 12 inbred strains of mice and an F2 intercross , 2003, Brain Research Bulletin.

[32]  P. Schoeffter,et al.  Regulation of CRH-induced secretion of ACTH and corticosterone by SOM230 in rats. , 2005, European journal of endocrinology.

[33]  G. Bissette,et al.  Somatostatin in Alzheimer's disease and depression. , 1992, Life sciences.

[34]  F. Bloom,et al.  Evidence for selective release of somatostatin-14 and somatostatin-28(1- 12) from rat hypothalamus , 1984, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[35]  E. Krause,et al.  The Degradation of Corticotropin-releasing Factor by Enzymes of the Rat Brain Studied by Liquid Chromatography–Mass Spectrometry , 1998, Peptides.

[36]  N. Ling,et al.  Primary structure of ovine hypothalamic somatostatin-28 and somatostatin-25. , 1980, Proceedings of the National Academy of Sciences of the United States of America.

[37]  P. Svenningsson,et al.  The significance of biochemical and molecular sample integrity in brain proteomics and peptidomics: Stathmin 2‐20 and peptides as sample quality indicators , 2007, Proteomics.

[38]  W. Vale,et al.  Central nervous system regulation of adrenocorticotropin secretion: role of somatostatins. , 1984, Endocrinology.

[39]  S. Bloom,et al.  Cerebellin-like peptide: TIssue distribution in rat and guinea-pig and its release from rat cerebellum, hypothalamus and cerebellar synaptosomes in vitro , 1988, Neuroscience.

[40]  P. Dutar,et al.  Somatostatin receptor subtypes 2 and 4 affect seizure susceptibility and hippocampal excitatory neurotransmission in mice , 2002, The European journal of neuroscience.

[41]  M. Herkenham,et al.  Long-term antidepressant administration alters corticotropin-releasing hormone, tyrosine hydroxylase, and mineralocorticoid receptor gene expression in rat brain. Therapeutic implications. , 1991, The Journal of clinical investigation.

[42]  D. Hoyer,et al.  Embryonic and postnatal mRNA distribution of five somatostatin receptor subtypes in the rat brain , 1995, Neuropharmacology.

[43]  D. Rubinow,et al.  CSF somatostatin in affective illness and normal volunteers , 1985, Progress in Neuro-Psychopharmacology and Biological Psychiatry.

[44]  F. Petraglia,et al.  SOMATOSTATIN AND OXYTOCIN INFUSION INHIBITS THE RISE OF PLASMA β‐ENDORPHIN, β‐LIPOTROPHIN AND CORTISOL INDUCED BY INSULIN HYPOGLYCAEMIA , 1986, Clinical endocrinology.

[45]  Masahiko Watanabe,et al.  Distinct expression of Cbln family mRNAs in developing and adult mouse brains , 2006, The European journal of neuroscience.

[46]  P. Svenningsson,et al.  Striatal Alterations of Secretogranin-1, Somatostatin, Prodynorphin, and Cholecystokinin Peptides in an Experimental Mouse Model of Parkinson Disease*S , 2009, Molecular & Cellular Proteomics.

[47]  A. Morel,et al.  The somatostatin-28 convertase of rat brain cortex generates both somatostatin-14 and somatostatin-28. , 1985, Biochemical and biophysical research communications.

[48]  D. Treit,et al.  Anxiolytic and antidepressant actions of somatostatin: the role of sst2 and sst3 receptors , 2009, Psychopharmacology.

[49]  K. Chihara,et al.  Repeated administration of antidepressant drugs reduces regional somatostatin concentrations in rat brain. , 1992, Journal of affective disorders.

[50]  Burton S. Rosner,et al.  Neuropharmacology , 1958, Nature.

[51]  David Fenyö,et al.  Neuropeptidomics Strategies for Specific and Sensitive Identification of Endogenous Peptides*S , 2007, Molecular & Cellular Proteomics.

[52]  G. Koob,et al.  Neurobiological Similarities in Depression and Drug Dependence: A Self-Medication Hypothesis , 1998, Neuropsychopharmacology.

[53]  J. Champagnat,et al.  Somatostatin depresses excitability in neurons of the solitary tract complex through hyperpolarization and augmentation of IM, a non-inactivating voltage-dependent outward current blocked by muscarinic agonists. , 1988, Proceedings of the National Academy of Sciences of the United States of America.

[54]  Dennis C. Choi,et al.  Central mechanisms of stress integration: hierarchical circuitry controlling hypothalamo–pituitary–adrenocortical responsiveness , 2003, Frontiers in Neuroendocrinology.

[55]  B. Penke,et al.  Somatostatin28(15–28), but not somatostatin28(1–12), affects central monoaminergic neurotransmission in rats , 1990, Neuropeptides.

[56]  G. Chrousos,et al.  Chronic imipramine is associated with diminished hypothalamic-pituitary-adrenal axis responsivity in healthy humans. , 1997, The Journal of clinical endocrinology and metabolism.

[57]  J. Licinio,et al.  The prototypic antidepressant drug, imipramine, but not Hypericum perforatum (St. John's Wort), reduces HPA-axis function in the rat. , 2003, Hormone and metabolic research = Hormon- und Stoffwechselforschung = Hormones et metabolisme.

[58]  W. Vale,et al.  Corticotropin Releasing Factor (CRF) Binding Protein: A Novel Regulator of CRF and Related Peptides , 1995, Frontiers in Neuroendocrinology.

[59]  Xiaorong Zhu,et al.  Analysis of peptides in prohormone convertase 1/3 null mouse brain using quantitative peptidomics , 2010, Journal of neurochemistry.

[60]  R. Duman,et al.  A Neurotrophic Model for Stress-Related Mood Disorders , 2006, Biological Psychiatry.